Clozapine Is Better Tolerated in Younger Patients: Risk Factors for Discontinuation from a Nationwide Database in Japan
Open Access
- 25 February 2021
- journal article
- research article
- Published by Korean Neuropsychiatric Association in Psychiatry Investigation
- Vol. 18 (2), 101-109
- https://doi.org/10.30773/pi.2020.0376
Abstract
Objective The effectiveness of clozapine is clearly superior to other antipsychotics in the treatment of refractory schizophrenia. Clozapine leads to various side effects, and therefore many patients are forced to discontinue. In this study, we analyzed the registry database of all cases in Japan to identify risk factors for discontinuation of clozapine. Methods The Clozaril patient monitoring service (R) (CPMS) database from July 31, 2009 to January 26, 2020 was acquired. We defined the following exclusion criteria: patients who had ever taken clozapine by a non-CPMS method, such as an individual import or clinical trial, patients who did not receive clozapine after being enrolled in CPMS, and patients with initial doses other than 12.5 mg (outside the current protocol). Therefore, all patients in this study are new users. Multivariate Cox regression analysis was used to investigate independent risk factors associated with time to discontinuation of clozapine. Results We identified 8,263 patients as the study population. Clozapine discontinuation was significantly associated with age 40 and older [hazard ratio (HR)=1.66, p<0.001], intolerance to olanzapine (HR=1.31, p=0.018), previous treatment with clozapine (HR=1.30, p=0.001), and leukocyte counts <6,000/mm(3) (HR=1.24, p<0.001). The Kaplan-Meier curves for clozapine discontinuation by age group revealed that older age at the time of clozapine introduction tended to have lower continuation rates. Conclusion Careful administration is important because patients with these factors have a high risk of discontinuation. In addition, the initiation of clozapine during the younger period was more effective and more tolerated.Keywords
This publication has 34 references indexed in Scilit:
- Predictors of clozapine discontinuation in patients with schizophreniaInternational Clinical Psychopharmacology, 2011
- Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up studyBMJ, 2006
- Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic TreatmentAmerican Journal of Psychiatry, 2006
- Schizophrenia and suicide: Systematic review of risk factorsThe British Journal of Psychiatry, 2005
- Continuation of clozapine treatment: practice makes perfectPsychiatric Bulletin, 2003
- Late-Onset Schizophrenia and Very-Late-Onset Schizophrenia-Like Psychosis: An International ConsensusAmerican Journal of Psychiatry, 2000
- Active monitoring of 12760 clozapine recipients in the UK and IrelandThe British Journal of Psychiatry, 1999
- Positive and negative symptom behaviors and caregiver burden in the relatives of persons with schizophreniaSchizophrenia Research, 1997
- Treatment-Resistant Schizophrenia - The Role of ClozapineCurrent Medical Research and Opinion, 1997
- Risk Factors for Clozapine Discontinuation Among 805 Patients in the VA Hospital SystemAnnals of Clinical Psychiatry, 1995